Long‐term survival analysis of patients with stage IIIB‐IV non‐small cell lung cancer complicated by type 2 diabetes mellitus: A retrospective propensity score matching analysis

Abstract

Abstract Background This study aimed to determine the effect of type 2 diabetes mellitus (T2DM) on overall survival (OS) of patients with stage IIIB–IV non‐small cell lung cancer (NSCLC). Methods We retrospectively analyzed patients with stage IIIB–IV NSCLC from January 2015 to December 2018 in the Department of Oncology at the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine. Kaplan–Meier plots, log‐rank tests, and Cox proportional hazards regression models were used to describe the effect of T2DM on the OS of patients with stage IIIB–IV NSCLC. Results This study collected data on 76 patients with NSCLC and T2DM (group A) and 214 NSCLC patients without T2DM (group B). After propensity score matching (PSM) analysis, 74 patients were included in each group. The mean OS of all patients was 17 months (range, 11–31 months). The mean OS of group A was 15 months (range, 8–25 months) and the mean OS of group B was 20 months (range, 14–39 months). The mean OS of group B was longer than group A, and the difference was statistically significant. Univariate analysis of the clinical data showed that T2DM and complications were significantly correlated with the prognosis of patients with stage IIIB‐IV NSCLC (p = 0.003 and p = 0.034). Multivariate Cox model analysis showed that T2DM and complications were independent prognostic factors for patients with stage IIIB–IV NSCLC (p = 0.002 and p = 0.024, respectively). Conclusion Stage IIIB–IV NSCLC patients without T2DM have an increased OS compared to patients with stage IIIB–IV NSCLE and T2DM.

Keywords

• non‐small cell lung cancer
• diabetes mellitus
• chemotherapy
• survival